Brainsway Ltd (BRSYF)
OTHER OTC:BRSYF
Want to see BRSYF full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
0.07Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Q1 2026
Earnings Call Date:May 13, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented a strong operational quarter with broad revenue and profitability gains, meaningful clinical and payer progress (notably SWIFT), a growing installed base and a solid cash position. Strategic investments (minority clinic stakes and Neurolief funding) and international momentum support long-term growth, but the company is making tradeoffs by increasing operating investments and remains partially dependent on payer coverage and milestone-driven commercialization paths. Overall, positives—robust top-line growth, margin expansion, RPO improvement and clinical validation—materially outweigh the risks, though execution and reimbursement timing will be critical to sustain momentum.Company Guidance
Strong Revenue Growth
Revenue of $15.5M in Q1 2026, up 35% year-over-year from $11.5M, driven by core business execution and expanded market penetration.
Robust Profitability and Margin Expansion
Reported 11th consecutive quarter of profitability: net income of $2.3M (over 100% increase vs. $1.1M prior year) and adjusted EBITDA of $2.8M, up 119% year-over-year.
Unit Shipments and Installed Base Expansion
Shipped 117 Deep TMS systems in the quarter (a 44% increase vs. prior year), bringing the installed base to approximately 1,820 systems.
Growing Remaining Performance Obligations (RPO)
Remaining performance obligations increased to $75M as of March 31, 2026, a 25% year-over-year rise (from roughly $60M), indicating stronger multi-year contract visibility.
Healthy Gross Profit and Operating Income Improvement
Gross profit rose to $11.6M (up 35% YoY from $8.6M) with healthy margins; operating income increased to approximately $2.0M from $0.6M in Q1 2025.
Strong Balance Sheet and Cash Position
Cash and cash equivalents of $58.9M as of March 31, 2026; company remains debt-free, enabling strategic investments and flexibility.
Breakthrough SWIFT Protocol Results and Adoption Momentum
SWIFT 6‑day acute protocol published data showing ~70% reduction in acute phase clinic visits; reported clinical outcomes of 88% response and 78% remission in 6 days; early payer adoption with expectations of coverage expansion to an estimated 40–50 million covered lives by year-end and initial large-payer draft/final policies.
Payer and Provider Reimbursement Wins
Evernorth eliminated prior authorization for TMS across Evernorth/Cigna; Optum updated policy allowing nurse practitioners to order/supervise/administer TMS across plans covering ~35M lives; other payers, VA and TRICARE moving similarly—reducing access constraints.
Clinical and Pipeline Progress
Multicenter patient recruitment underway for Deep TMS in alcohol use disorder; preparing FDA submission for PTSD symptoms in MDD (targeting clearance by year-end, ~90-day initial review expectation).
Strategic Investments to Expand Market Reach
Completed minority investments in 5 mental health networks and signed new deal with Hopemark ($1.5M initial, up to $1.5M additional); identified 200+ potential clinics for program expansion to drive commercial/clinical channels.
Complementary Technology Partnership with Neurolief (ProlivRx)
Increased convertible loan investment in Neurolief to $11M (additional $6M completed in late March) with potential $5M tranche; ProlivRx secured VA federal supply schedule and pricing of $11,800 per unit, enabling VA commercialization and home-use neuromodulation complementing Deep TMS.
Company Guidance for 2026
Full-year revenue guidance of $66M–$68M (27%–30% YoY growth expected); operating income guidance of 13%–14% of revenue; adjusted EBITDA guidance of $12M–$14M (projected 86%–100% increase vs. 2025).
BRSYF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BRSYF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $16.84 | $16.84 | +0.03% |
Mar 11, 2026 | $11.87 | $11.87 | 0.00% |
Nov 11, 2025 | $8.00 | $7.88 | -1.50% |
Aug 13, 2025 | $5.49 | $5.49 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Brainsway Ltd (BRSYF) report earnings?
Brainsway Ltd (BRSYF) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
What is Brainsway Ltd (BRSYF) earnings time?
Brainsway Ltd (BRSYF) earnings time is at Aug 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BRSYF EPS forecast?
Currently, no data Available